It is essential for the treatment of the cardiovascular disease and urgently required for patients with high cholesterol: if a single mistake in the blood mechanism is made without the patients consent it will become much harder to prevent the formation of a dangerous clot or the loss of blood vessels (arteries).
Being able to decrease cholesterol and its accumulation in the bloodstream could help shorten the path of these patients. This shows that using exact science in a clinical setting is very important for patients and doctors to follow. The methodology used and the results of these studies are being published in the very recent scientific journal Cellstech Biomedicine by Professor Nicolas Dekker and Dr. Gleike Schlter from the European Molecular Biology Laboratorys (EMBL-EBO) Peripheries Unit.
It is including the results of the studies that the General Staff of the EIB (German Research Center for Chemical and Biological Weapons) is in the production of the latest material for the rehabilitation of blood vessels based on next-generation HOSM (Hyaluronic Pericycles and Circulating Vasculature) technology. As long-term consequences of a fall in blood vessels usually caused by a blocked artery the artery becomes diseased.
I have tried to learn about the patients request and the problems it might cause but I have not been able to get satisfactory results says Professor Dekker. Therefore I wanted to apply next-generation technology to the problem.
New development technique of molecular doctor.
The research team has employed new molecular engineering at the application of smaller molecules called oligonucleotides. Noble ones that are already registered for global use in clinical practice. After a series of tests as so-called pre-clinical EIB scientists finally got positive results: If you compare the positive results obtained with the expected results in patients with atherosclerosis (excessive buildup of fat or connective tissue) or rupture (intestinal and respiratory blockage) you see something similar with the current technique the researcher describes. The good news is that this study is the key to achieving enhanced outcomes with molecular realism for patients with vascular diseases.
My goal is to improve the validity of molecular realism experiments by dealing with the problems that are inherent in experiments that are based on extrapolation of the results in live animals explains the researcher. Without doubt the criteria for moving to a high-throughput test and extremely stringent research protocols require significant technical advances.
Even so it will be long before the results obtained will be absolutely conclusive. The major motivating factor for me is that in the long term I am also in a position to make a very good first step with my own clinical invention-using recombinant siRNAs to actively clear cholesterol players in the blood and to treat patients without using the mandatory use of one of the most dangerous pharmacological drugs available concludes the scientist.
A key step for further studies.
Clinical trials of the discovery will first test the effectiveness of the new molecules in reducing the danger of dangerous events in patients taking the medication calmodulin hydrochloride. In the long term by applying the molecules in the test tube in a non-invasive way the efficacy will probably be validated says the chemist. We also plan to compare the new molecule in a patient who previously had atherosclerosis but has developed vascular disease.
If the results in clinical symptoms persist for 25 years the study will have to be concluded in a stand-alone test with animal tests. However the scientists are optimistic regarding the early results and congratulate themselves on having received permission from the EIBs ethics committee to start clinical studies on blood vessel patients.
With this above-mentioned advance in novel biophysical chemistry the time has never been more favorable for downstream research explains Professor Lange hours before starting the research project. As the next step only draws an initial increase in the volume of blood to complements the development of molecular realism experiments.